|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Examining the evidence:complementary adjunctive therapies for multiple sclerosis显示文摘 | Namaka M Crook A Doope A | 2008 | Neuro Res2008，30，7： | 1 |
| 2 | A treatment algorithm for neuropathic pain显示文摘 | Namaka M Gramlich CR Ruhlen D | 2004 | Clin Ther2004，26，： | 1 |
| 3 | A treatment algorithm for neuropathic pain显示文摘 | Namaka M Gramlich CR Ruhlen D Melanson M Sutton I Major J | | 0，，： | 1 |
| 4 | Molecular mimicry and multiple sclerosis显示文摘Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system.Although the exact underlying mechanism leading to myelin destruction is unknown,the molecular mimicry theory is the most commonly acknowledged elucidation of MS pathology.Although various antigens have been associated with MS induction,this review presents studies focused on key bacterial and viral antigens that lead to the development of MS.The research specific to a molecular mimicry theory of MS via each implicated agent is weak;however,collectively the reports provide credible support for this theory.Given that homologous sequences are not required to lead to antigenic cross-reactivity,it is reasonable to conclude that certain viral and bacterial antigens with 5-10 similar amino acids in sequence can lead to self destruction of similar myelin sequences.Thus,this literature review has provided insight to further the understanding of the etiology of multiple sclerosis. | Michael Namaka Sabina Kapoor Leann Simms Christine Leong Amy Grossberndt Michael Prouta Emma Frost Farid Esfahani Andrew Gomori Michael R. Mulvey | 2011 | Neural Regeneration Research2011，6，17： | 1 |
| 5 | Neurogenesis in postnatal mouse dorsal root ganglia显示文摘 | Namaka MP Sawchuk M MacDonald SC | | 0，，： | 1 |
| 6 | A treatment al- gorithm for neuropathic pain显示文摘 | Namaka M Gramlich CR Ruhlen D | 2004 | Clin Ther2004，26，7： | 1 |
| 7 | Paroxetine vs pregabalin for the management of neuropathic pain in multiple sclerosis显示文摘AIM: To compare the effectiveness and tolerability of paroxetine vs pregabalin for the management of multiple sclerosis(MS)-induced neuropathic pain(NPP).METHODS: A randomized, flexible-dose open-label 8-wk study involving 21 relapsing-remitting MS patients with MS-induced NPP was conducted to evaluate the effectiveness and tolerability of pregabalin versus paroxetine for pain management. The trial included a 3-wk dose titration phase followed by a 5-wk stable dose phase. Primary outcome measures included daily patient-reported pain intensity as measured using a 100 mm visual analogue scale(VAS pain) and daily impact of pain on daily activities(VAS impact). Hierarchical regression modeling was conducted on each outcome to determine if within person VAS trajectory for pain and impact differed across study groups, during 56 d follow-up. RESULTS: Attrition rates were significantly greater(P < 0.001) in the paroxetine versus pregabalin study group(70% vs 18.2%, respectively). Average study duration between study groups also significantly differed(P < 0.001). Paroxetine participants completed an average of 27.3 d of treatment vs 49.5 d in the pregabalin group, with the majority of patients withdrawing due to adverse events. Due to the high attrition rates in the paroxetine study arm, the investigators stopped the study prior to achieving complete recruitment. As such, no significant differences between pregabalin and paroxetine study arms were noted for the primary outcome measures(VAS pain, VAS impact). Comparative assessment of baseline patient characteristics also revealed no significant differences between the study arms. CONCLUSION: High attrition rates associated with paroxetine use suggest that it be used with caution for MS-induced NPP. Efficacy outcomes could not be assessed due to attrition. | Dana A Turcotte Malcolm Doupe Mahmoud Torabi Andrew J Gomori Karen Ethans Farid Esfahani Katie Galloway Michael P Namaka | 2014 | World Journal of Anesthesiology2014，3，2： | 1 |
| 8 | Opioid misuse in Canada and critical appraisal of aberrant behavior screening tools显示文摘The incidence of prescription opioid misuse in Canada is increasing. Initiatives for safe prescribing practices for opioid medications include risk assessment for current and future opioid misuse. A clinical screening tool that can be universally applied to all patient populations is currently not available. Our objective was to provide a brief narrative review on opioid misuse from a Canadian perspective as well as a critical appraisal of the available clinical screening tools for detecting aberrant behaviors associated with opioid misuse. The Drug Abuse Screening Test, Addiction Behaviors Checklist, Diagnosis, Intractability, Risk and Efficacy Inventory, Pain Assessment and Documentation Tool, Prescription Drug Use Questionnaire, Prescription Opioid therapy Questionnaire, Screener and Opioid Assessment for Patients with Pain(SOAPP), Revised SOAPP, Pain Medication Questionnaire, Opioid Risk Tool and Current Opioid Misuse Measure were included in the following review. Overall, a wide variability in quality, sensitivity and specificity was observed between screening tools. There is an overall lack of applicability to diverse patient populations as the majority of screening tools have been validated in pain clinic populations only. To conclude, there is a great need for a validated and convenient aberrant behaviors risk assessment tool that can be applied to a diverse patient population in a clinical setting. | Grace EC Frankel Howard Intrater Malcolm Doupe Michael Namaka | 2014 | World Journal of Anesthesiology2014，3，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员